Maumee, OHNCT07154823Now EnrollingIRB Ready

Acute Myeloid Leukaemia (AML) Clinical Trial in Maumee, OH

Access cutting-edge acute myeloid leukaemia (aml) treatment through this clinical trial at a research site in Maumee. Study-provided care at no cost to qualified participants.

Sponsored by Tempus AI

Quick Self-Assessment

See if you qualify for this Maumee location

Preparing your pre-screening questions…

Expert Care in Maumee

Access acute myeloid leukaemia (aml) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute myeloid leukaemia (aml) treatment provided free

Apply for This Maumee Location

Check if you qualify for this acute myeloid leukaemia (aml) clinical trial in Maumee, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Maumee

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Maumee site if eligible
  4. 4Begin participation

About This Acute Myeloid Leukaemia (AML) Study in Maumee

The TEMPUS AQUARIUS Study is a non-interventional, longitudinal observational study focused on hematological malignancies. It will collect rich molecular (multi-omic) and clinical data from patient cohorts through serial blood draws and the acquisition of leftover tissue and/or bone marrow aspirates during their routine therapy and disease monitoring. The primary goal is to understand the association between biomarkers and real-world clinical outcomes in these patient populations.

Sponsor: Tempus AI

Who Can Participate

Inclusion Criteria

Willing and able to participate in the research and provide biospecimens
Willing and able to provide informed consent Cohort 001 Inclusion:
Have documented diagnosis of AML according to the World Health Organization (WHO) classification
Secondary AML is allowed Cohort 002 Inclusion:
Histologically confirmed diagnosis of Follicular Lymphoma (Subgroups A-D)
Submission of baseline sample representative of current disease per laboratory manual (Subgroups A-D)
002A (Newly Diagnosed Active Observation): On active observation for 6 more or less, or intended for active observation
002B (Newly Diagnosed, High Risk): Intended for first line treatment
002B (Newly Diagnosed, High Risk): Meets the criteria for high risk by any of the following: Follicular Lymphoma Inernational Prognostic Index (FLIPI) High Risk, Groupe d'Etude des Lymphomes Follicularies (GELF) High Tumor Burden, Lactate Dehydrogenase (LDH) above the upper limit of normal (ULN)
002C (Relapsed / Refractory High Risk POD24 FL): Documented progression of disease within 24 months (POD24) of first line follicular lymphoma treatment, prior to second line treatment
002D (Transformed FL): Pathologically confirmed transformation All Cohorts

Exclusion Criteria

1\. Not willing or able to adhere with the study procedures Cohort 001: 1\. Have received any prior therapy intended for standard of care (SoC) treatment of AML Cohort 002:
002A: Received prior treatment for follicular lymphoma
002A: Diagnosed with High Risk follicular lymphoma by any of the following definitions: FLIPI High Risk, GELF High Tumor Burden, LDH above ULN
002A: Resected patients with NED
002B: Intended for active observation
002B: Received prior treatment for follicular lymphoma

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Maumee?

Yes, this clinical trial (NCT07154823) has an active research site in Maumee, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Myeloid Leukaemia (AML) Treatment Options in Maumee, OH

If you're searching for acute myeloid leukaemia (aml) treatment options in Maumee, OH, this clinical trial (NCT07154823) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Maumee research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute myeloid leukaemia (aml) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all acute myeloid leukaemia (aml) clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Maumee, OH

See all leukemia clinical trials recruiting in Maumee — not just this study.

Browse Leukemia Trials in Maumee →

Browse More Trials by Condition

Leukemia TrialsAcute Myeloid Leukemia TrialsHeart Attack TrialsMyocardial Infarction TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Maumee?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Maumee, OH